Taiho Pharmaceutical Co., Ltd. – Oncology, Allergy and Immunology R&D Division of Otsuka Holdings
- Company Name: Taiho Pharmaceutical Co., Ltd.
- State/Prefecture: Tokyo Prefecture
- City/Town/Village: Chiyoda-ku
- Street: 1-27 Kandanishiki-cho
- Country: Japan
- Zip/Postal Code: 101-8444
- Phone: +81-3-3294-4527
- Website: https://www.taiho.co.jp/en/
- Contact: https://www.taiho.co.jp/en/contact
- Listed: 10/16/2018 3:34 pm
- Expires: This ad has expired
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma focusing on the three fields of oncology, allergy and immunology, and urology. In the field of oncology, in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts.
In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people’s efforts to lead fulfilling and rewarding lives.
The company was established in 1963 and headquartered in Tokyo. There are 22 branches and 53 offices and 5 plants in Japan. Taiho is a full member of the Japan Pharmaceutical Manufacturers Association (JPMA).
Taiho Ventures, venture capital arm of Taiho Pharmaceutical, increased investment from US$50M to US$300M for innovative biotech start-ups
Date: Date: Oct. 16, 2018
Source: Taiho Ventures, LLC
Taiho Ventures, LLC, a strategic corporate venture capital arm of Taiho Pharmaceutical, Co., Ltd., announced on October 16 that Taiho Ventures increased its investment pool by US$250 million from the initial US$50 million to US$300 million. The increase in the investment pool illustrates Taiho Ventures’ strong commitment to its continuous support of innovative biotech start-ups pursuing cutting-edge drug discovery activities based on state-of-the-art science. Taiho Pharmaceutical also aims to accelerate its open innovation through these investment efforts.
Continue reading »